Validation protocol and analytical quality in biological monitoring of occupational exposure to antineoplastic drugs

Toxicology Letters

Volumn 162, Issue 2-3 SPEC. ISS., 2006, Pages 256-262

  Turci, Roberta ^a   Sottani, Cristina ^a   Schierl, Rudolf ^b   Minoia, Claudio ^a  

^a IRCCS   (Italy)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Antineoplastic drugs; Biological monitoring; Quality assurance; Uncertainty of measurement

Indexed keywords

AMSACRINE; ANTINEOPLASTIC AGENT; AZACITIDINE; AZATHIOPRINE; AZIRIDINE; BLEOMYCIN; BUSULFAN; CARCINOGEN; CARMUSTINE; CHLORAMBUCIL; CHLORNAPHAZINE; CHLOROZOTOCIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; LOMUSTINE; MELPHALAN; MITOMYCIN C; MITOXANTRONE; PROCARBAZINE; SARCOLYSIN; SEMUSTINE; STREPTOZOCIN; TENIPOSIDE; THIOTEPA; TREOSULFAN; UNINDEXED DRUG;

ACCURACY; ANALYTIC METHOD; ANALYTICAL PARAMETERS; ARTICLE; BIOLOGICAL MONITORING; DRUG MONITORING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; OBSERVER VARIATION; OCCUPATIONAL EXPOSURE; OCCUPATIONAL SAFETY; PRIORITY JOURNAL; QUALITY CONTROL; RELIABILITY; REPRODUCIBILITY; SOLID PHASE EXTRACTION; TANDEM MASS SPECTROMETRY; VALIDATION PROCESS;

ANTINEOPLASTIC AGENTS; ENVIRONMENTAL MONITORING; HUMANS; INHALATION EXPOSURE; OCCUPATIONAL EXPOSURE; PERSONNEL, HOSPITAL; REPRODUCIBILITY OF RESULTS; SKIN ABSORPTION; UNCERTAINTY;

EID: 32644437821     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxlet.2005.09.022     Document Type: Article

References (31)

1. American Society of Hospital Pharmacists ASHP technical assistance bulletin on handling cytotoxic and hazardous drugs Am. J. Hosp. Pharm. 47 1990 1033 1049
2. R.P. Bos, B.F.J. Weissenberger, and R.B.M. Anzion α-Fluoro-β- alanine in urine of workers occupationally exposed to 5-fluoruracil in a 5-fluoruracil-producing factory Biomarkers 3 1 1998 81 87
3. S. Burgaz, B. Karahalil, P. Bayrak, L. Taskin, F. Yavuzaslan, I. Bokesoy, R.B. Anzion, R.P. Bos, and N. Platin Urinary cyclophosphamide excretion and micronuclei frequencies in peripheral lymphocytes and in exfoliated buccal epithelial cells of nurses handling antineoplastics Mutat. Res. 439 1 (February) 1999 97 104
4. L.C. Burton, and C.A. James Rapid method for the determination of ifosfamide and cyclophosphamide in plasma by high performance liquid chromatography with solid-phase extraction J. Chromatogr. B Biomed. Sci. Appl. 431 1988 450 454
5. Canadian Society of Hospital Pharmacists, 1993. Guidelines for the handling and disposal of hazardous pharmaceuticals (including cytotoxic drugs), Ottawa, Ontario, Canada.
6. Clinical Oncological Society of Australia Guidelines and recommendations for safe handling of antineoplastic agents Med. J. Aust. 1 1983 426
7. A.S. Ensslin, Y. Stoll, A. Pethran, A. Pfaller, H. Rommelt, and G. Fruhmann Biological monitoring of cyclophosphamide and ifosfamide in urine of hospital personnel occupationally exposed to cytostatic drugs Occup. Environ. Med. 51 1994 229 233
8. A.S. Ensslin, A. Pethran, R. Schierl, and G. Fruhmann Urinary platinum in hospital personnel occupationally exposed to platinum-containing antineoplastic drugs Int. Arch. Occup. Environ. Health 65 1994 339 342
9. EURACHEM/CITAC Guide, 2000. Quantifying Uncertainty in Analytical Measurement, second ed.
10. C.T.A. Evelo, R.P. Bos, J.G.P. Peter, and P.Th. Henderson Urinary cyclophosphamide assay as a method for biological monitoring of occupational exposure to cyclophosphamide Int. Arch. Occup. Environ. Health 58 1986 151 155
11. K. Falck, P. Grohn, M. Sorsa, H. Vainio, E. Heinonen, and L.R. Holsti Mutagenicity in urine of nurses handling cytostatic drugs Lancet 1 1979 1250 1251
12. C.H. Grimm, and K.-S. Boos J. Angerer K.H. Schaller Analyses of Hazardous Substances in Biological Materials 2001 VCH Weinheim 119 (Chapter 7)
13. M. Hirst, D.G. Millis, S. Tse, L. Levin, and D.F. White Occupational exposure to cyclophosphamide Lancet 1 1984 186 188
14. International Agency for Research on Cancer, 2004. Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans: Pharmaceutical Drugs. International Agency for Research on Cancer, Lyon, France, www.iarc.fr.
15. R.M. Mader, B. Rizovski, G.G. Steger, H. Rainer, R. Proprentner, and R. Kotz Determination of methotrexate in human urine at nanomolar levels by high-performance liquid chromatography with column switching J. Chromatogr. 613 1993 311 316
16. National Institute for Occupational Safety and Health (NIOSH), 2004. Preventing Occupational Exposure to Antineoplastic and other Hazardous Drugs in Healthcare Settings. Prepublication copy, June 7, 2004.
17. O. Nygren, and C. Lundgren Determination of platinum in workroom air and in blood and urine from nursing staff attending patients receiving cisplatin chemotherapy Int. Arch. Occup. Environ. Health 70 3 1997 209 214
18. Occupational Safety and Health Administration, 2000. OSHA Technical Manual. Hospital Investigations: Health Hazard. Section VI.
19. Pethran, A., Schierl, R., Hauff, K., Grimm, C.H., Boos, K.S., Nowak, D., 2003. Uptake of antineoplastic agents in pharmacy and hospital personnel. Part I: monitoring of urinary concentrations. Int. Arch. Occup. Environ. Health 76 (1), 5-10, Epub 2002 Oct 09.
20. Provvedimento 5 agosto Documento di linee-guida per la sicurezza e la salute dei lavoratori esposti a chemioterapici antiblastici in ambiente sanitario G.U. 236 1999 7.10.1999
21. N. Sannolo, N. Miraglia, M. Biglietto, A. Acampora, and A. Malorni Determination of cyclophosphamide and ifosfamide in urine at trace levels by gas chromatography/tandem mass spectrometry J. Mass Spectrom. 34 1999 845 849
22. P.J.M. Sessink, K.A. Boer, A.P.H. Scheefhals, R.B.M. Anzion, and R.P. Bos Occupational exposure to antineoplastic agents at several departments in a hospital: environmental contamination and excretion of cyclophosphamide and ifosfamide in urine of exposed workers Int. Arch. Occup. Environ. 64 1992 105 112
23. P.J.M. Sessink, M.M. Scholtes, R.B.M. Anzion, and R.P. Bos Determination of cyclophosphamide in urine by gas chromatography-mass spectrometry J. Chromatogr. B Biomed. Sci. Appl. 616 1993 333 337
24. ®) in human plasma Rapid Commun. Mass Spectrom. 12 1998 251 255
25. C. Sottani, R. Turci, L. Perbellini, and C. Minoia Liquid-liquid extraction procedure for trace determination of cyclophosphamide in human urine by high-performance liquid chromatography tandem mass spectrometry Rapid Commun. Mass Spectrom. 12 1998 1063 1068
26. C. Sottani, M. Zucchetti, M. Zaffaroni, M. Bettinelli, and C. Minoia Validated procedure for simultaneous trace level determination of the anti-cancer agent gemcitabine and its metabolite in human urine by high-performance liquid chromatography with tandem mass spectrometry Rapid Commun. Mass Spectrom. 18 10 2004 1017 1023
27. C. Sottani, G. Tranfo, M. Bettinelli, P. Faranda, M. Spagnoli, and C. Minoia Trace determination of anthracyclines in urine: a new high-performance liquid chromatography/tandem mass spectrometry method for assessing exposure of hospital personnel Rapid Commun. Mass Spectrom. 18 20 (October) 2004 2426 2436
28. R. Turci, M.L. Fiorentino, C. Sottani, and C. Minoia Determination of methotrexate in human urine at trace levels by solid phase extraction and high-performance liquid chromatography/tandem mass spectrometry Rapid Commun. Mass Spectrom. 14 2000 173 179
29. R. Turci, C. Sottani, A. Ronchi, and C. Minoia Biological monitoring of hospital personnel occupationally exposed to antineoplastic agents Toxicol. Lett. 134 1-3 (August) 2002 57 64
30. R. Turci, C. Sottani, G. Spagnoli, and C. Minoia Biological and environmental monitoring of hospital personnel exposed to antineoplastic agents: a review of analytical methods J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 789 2 (June) 2003 169 209
31. S. Venitt, C. Crofton-Sleigh, J. Hunt, V. Speechley, and K. Briggs Monitoring exposure of nursing and pharmacy personnel to cytotoxic drugs: urinary mutation assays and urinary platinum as markers of absorbtion Lancet 1 1984 74 77